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Outcome of Mildly Symptomatic or
Asymptomatic Obstructive Hypertrophic Cardiomyopathy
A Long-Term Follow-Up Study
Paul Sorajja, MD,* Rick A. Nishimura, MD,* Bernard J. Gersh, MB, CHB, DPHIL,*
Joseph A. Dearani, MD,† David O. Hodge, MS,‡ Heather J. Wiste, BA,‡ Steve R. Ommen, MD*
Rochester, Minnesota
Objectives The purpose of this study was to characterize the prognosis of minimally symptomatic patients with obstructive
hypertrophic cardiomyopathy (HCM).
Background Recent data have suggested that obstruction may be present in the majority of HCM patients, irrespective of
cardiac symptoms. The prognosis of minimally symptomatic obstructive HCM remains poorly defined.
Methods We examined 544 consecutive adult patients (age 59  16 years; 55% men) with obstructive HCM docu-
mented by Doppler echocardiography who were free of severe cardiac symptoms, and we performed clinical
follow-up (median 9.3 years).
Results There was only a slight excess mortality of the cohort in comparison to the expected survival of a similar U.S.
general population (10-year observed vs. expected survival, 69.3% vs. 71.9%; p  0.04) and 46% of the deaths
were attributable to noncardiac causes. However, there was a clear relation between increasing severity of the
left ventricular outflow tract (LVOT) gradient and outcome. For patients with high resting gradients (Doppler peak
velocity 4 m/s), survival was significantly impaired (53% at 10 years; p  0.001 vs. expected), and death or
severe symptoms occurred in 68% of these patients within 10 years after the initial evaluation. Conversely, there
was no impairment of long-term survival for patients with less-severe resting obstruction. Independent predictors
of mortality in the entire cohort were age, prior stroke, and LVOT gradient severity.
Conclusions Patients with obstructive HCM and mild or no symptoms have only slight excess mortality. However, patients
with markedly elevated resting LVOT gradients are at a high risk of heart failure and death. These findings may
have important implications for therapy, including the timing of septal reduction therapy. (J Am Coll Cardiol
2009;54:234–41) © 2009 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.01.079H
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bynamic left ventricular outflow tract (LVOT) obstruction
s an important component of the pathophysiology of
ypertrophic cardiomyopathy (HCM), arising from an in-
erplay of drag effects, Venturi forces, and systolic anterior
otion of the mitral valve (1–4). The prognosis of HCM
atients with obstruction is poorer than that of those
ithout obstruction, especially in the patients with severe
ymptoms (5–8). For patients with obstructive HCM and
evere symptoms, surgical myectomy is the therapeutic gold
tandard and provides hemodynamic and symptom relief
ith a low operative risk in appropriate candidates (9–11).
rom the *Division of Cardiovascular Diseases and Internal Medicine, †Division of
ardiovascular Surgery, and the ‡Department of Biostatistics, Mayo Clinic College of
edicine, Rochester, Minnesota. Bernard J. Gersh is an advisory board member for
straZeneca, Boston Scientific, Bristol-Myers Squibb, and Abbott Laboratories; and
as stock options with CV Therapeutics.o
Manuscript received November 2, 2008; revised manuscript received January 7,
009, accepted January 12, 2009.owever, it is unclear as to whether intervention should be
erformed in patients with mild or no symptoms, because
he outcome of minimally symptomatic patients with ob-
tructive HCM has not been delineated. Accordingly, this
tudy was undertaken to evaluate the long-term outcome of
atients with minimally symptomatic, obstructive HCM.
ethods
atients. This study was approved by the Mayo Clinic
nstitutional Review Board. Consecutive patients with the
ollowing criteria were enrolled: 1) age 18 years; 2) the
resence of obstructive HCM; 3) self-reported mild or no
ardiac symptoms; 4) absence of need for cardiac surgery that
ould lead to concomitant myectomy (e.g., endocarditis, aortic
oot surgery); 5) absence of prior cardiac arrest; and
) informed consent for study participation. The presence of
oth New York Heart Association (NYHA) functional class II
r lower and Canadian Cardiac Society (CCS) angina class II
o
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July 14, 2009:234–41 Minimally Symptomatic Obstructive HCMr lower were required to define mild or no cardiac symptoms
5,12). Each of these patients was evaluated for obstructive
CM between January 1, 1982, and December 31, 2005, at
he Mayo Clinic in Rochester, Minnesota. The selection of this
ntry date was based upon the initial availability of Doppler
chocardiography for calculation of the LVOT gradient at our
nstitution. The diagnosis of HCM was based on typical
linical, electrocardiographic, and echocardiographic features,
ith ventricular myocardial hypertrophy (end-diastolic wall
hickness 15 mm) occurring in the absence of any other
ardiac or systemic disease that could have been responsible for
he hypertrophy (13,14). The magnitude of myocardial hyper-
rophy was assessed with M-mode and 2-dimensional trans-
horacic echocardiography using standard techniques. Patients
ith peak LVOT velocity 2.7 m/s underwent provocation
ith either Valsalva strain or amyl nitrite inhalation per
tandard protocol in the echocardiographic laboratory. In this
rotocol, Valsalva strain or amyl nitrite (0.3 ml) inhalation is
erformed to change ventricular load during simultaneous
oppler and 2-dimensional echocardiography. The peak
VOT velocity is averaged from 3 to 5 cardiac cycles recorded
t a sweep speed of 50 to 100 mm/s. LVOT obstruction was
efined by Doppler echocardiography as a systolic anterior
otion of the mitral valve and an LVOT (subaortic) velocity of
2.7 m/s at rest of 3.5 m/s with provocation, which is
espectively comparable to an LVOT gradient30 mm Hg at
est or 50 mm Hg with provocation (5,6,9). In all cases,
articular consideration was given to distinguishing the Dopp-
er signal of LVOT obstruction from that of mitral regurgita-
ion. The initial clinical evaluation was defined as the point at
hich obstructive HCM was first identified at the Mayo Clinic.
ollow-up. Vital status, cardiac symptoms, and need for
eptal reduction therapy (e.g., surgical myectomy, percutaneous
lcohol septal ablation) were ascertained by follow-up evalua-
ion consisting of mailed questionnaires, telephone contact,
nd interrogation of the Social Security Death Index (11,15).
or deceased patients, procurement of death certificates and
nterviews with next of kin was performed to determine cause
f death. Death due to congestive heart failure was defined as
eath occurring in the context of long-standing cardiac decom-
ensation with progression of the disease over the preceding
ear with the development of pulmonary edema or cardiogenic
hock. Sudden cardiac death was defined as instantaneous
nd unexpected death with or without documented ventric-
lar fibrillation within 1 h after a witnessed collapse, in
atients who previously were in stable clinical condition, or
octurnal death with no antecedent history of worsening
ymptoms (11,15). Appropriate discharge of an implantable
ardioverter-defibrillator (ICD) device for therapy of a lethal
rrhythmia (i.e., sustained ventricular tachycardia or fibrilla-
ion) was considered to be sudden cardiac death. HCM-related
eath was defined as occurrence of death due to either
ongestive heart failure or stroke, sudden cardiac death or
ppropriate discharge of an ICD device for treatment of lethal
rrhythmia, occurrence of cardiac transplantation, or death in ohe absence of pre-mortal caus-
tive conditions (e.g., malignancy)
16).
ata analysis. Study end points
ere all-cause mortality, death
ue to HCM-related causes, and
he combination of all-cause
ortality and occurrence of se-
ere symptoms (NYHA func-
ional class III or greater or CCS
ngina class III or greater) fol-
owing the initial clinical visit.
he Kaplan-Meier method was
sed to estimate survival of the
arious end point events with
5% confidence intervals (CIs). Expected survival was cal-
ulated using age- and sex-specific mortality rates for the
ear of entry into the study obtained from the U.S. general
opulation. These rates specified all-cause mortality, were
alculated for each individual in the study, and were
ombined to form an expected summary curve for the
opulation (11,16,17). Observed mortality was compared to
xpected survival using a 1-sample log-rank test for the
aseline Clinical VariablesTable 1 Baseline Clinical Variables
Age (yrs) 59 16
Male sex 297 (54.6)
NYHA functional class
I 335 (61.6)
II 209 (38.4)
CCS class
I 433 (79.6)
II 111 (20.4)
Atrial fibrillation 70 (12.9)
Prior stroke 30 (5.5)
Hypertension 184 (33.8)
Diabetes mellitus 25 (4.6)
Coronary artery disease 36 (6.6)
Family history of HCM 91 (16.7)
Family history of sudden death due to HCM 65 (12.0)
Interventricular septal thickness (mm) 18.9 5.1
Posterior wall thickness (mm) 13.0 2.8
End-diastolic diameter (mm) 44.0 6.6
End-systolic diameter (mm) 24.0 5.4
Left atrial diameter (mm) 45.1 8.7
Resting left ventricular outflow tract gradient (mm Hg) 40.9 35.8
30 mm Hg 270 (49.6)
Internal cardioverter-defibrillator 6 (1.0)
Permanent pacemaker 13 (2.2)
Medications
Beta-receptor antagonist 250 (46.0)
Calcium-channel blocker 156 (28.7)
Disopyramide 26 (4.8)
Amiodarone 15 (2.8)
Warfarin 25 (4.6)
alues are mean  SD or n (%).
Abbreviations
and Acronyms
CCS  Canadian
Cardiovascular Society
CI  confidence interval
HCM  hypertrophic
cardiomyopathy
ICD  implantable
cardioverter-defibrillator
LVOT  left ventricular
outflow tract
NYHA  New York Heart
AssociationCCS  Canadian Cardiac Society; HCM  hypertrophic c
utflow tract; NYHA  New York Heart Association.ardiomyopathy; LVOT  left ventricular
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Minimally Symptomatic Obstructive HCM July 14, 2009:234–41ntire follow-up period. For purposes of data analysis,
atients were grouped according to severity of the LVOT
radient at rest (peak LVOT velocity 3, 3 to 4, and 4
/s). These categories of severity were chosen on the basis
f prior investigations of patients with aortic valvular ste-
osis that have been used to identify high-risk asymptom-
tic patients (16,18,19).
Univariate models were first constructed to determine
hich variables were associated with the end point of
ll-cause mortality. Variables considered were age, male sex,
nown coronary artery disease, atrial fibrillation, prior
troke, diabetes mellitus, hypertension, resting LVOT gra-
ient, maximal left ventricular wall thickness, use of beta-
eceptor antagonist, left atrial volume index, posterior wall
hickness, left ventricular end-diastolic dimension, and left
entricular end-systolic dimension. Variables that were sig-
ificant at the 0.05 level were then considered for a
Figure 1 Observed Versus Expected Survival of Patients
With Obstructive Hypertrophic Cardiomyopathy
Expected survival was calculated from age- and
sex-matched U.S. general population mortality rates and year of entry.
linical Events During Follow-UpTable 2 Clinical Events During Follow-Up
Event Patients, n (%)
Any death 178 (32.7)
Noncardiac cause 81 (14.9)
HCM-related 82 (15.1)
Sudden cardiac death 10 (1.8)
Stroke 6 (1.1)
Unknown cause 15 (2.8)
Any death or severe symptoms* 248 (45.6)
Severe symptoms* 70 (12.9)
HCM-related death or severe symptoms* 176 (32.4)
Death or septal reduction therapy 215 (39.5)
Septal reduction therapy 51 (9.4)
Surgical septal myectomy 47 (8.6)
Alcohol septal ablation 4 (0.7)
Severe symptoms were defined as NYHA functional class III or IV dyspnea or CCS class III or IV
ngina.
Abbreviations as in Table 1.Figure 2 Relation of Survival to Severity
of the Resting Peak LVOT Velocity
(A) Observed versus expected survival for patients with resting peak left
ventricular outflow tract (LVOT) velocity 3 m/s. (B) Observed versus
expected survival for patients with resting peak LVOT velocity 3 to 4 m/s.
(C) Observed versus expected survival for patients with resting peak LVOT
velocity 4 m/s. Overall survival was significantly poorer for patients with
high peak LVOT gradients (velocity 4 m/s), but not for patients with lower
gradient thresholds.
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July 14, 2009:234–41 Minimally Symptomatic Obstructive HCMultivariate model. Forward and backward stepwise tech-
iques using the PHREG procedure in SAS verison 9.1.3
SAS Institute, Cary, North Carolina) were used to identify
hich variables were independently associated with each
nd point at a significance level of p  0.05 and thus
ncorporated into a final multivariate model. Left atrial
olume index, posterior wall thickness, end-diastolic dimen-
ion, and end-systolic dimension were not included in the
tepwise model even if univariately significant due to the
ignificant number patients with missing data (17% to 26%).
omparisons of continuous variables were made with the
ppropriate 2-sample test: a 2-sample t test in cases in which
he variable distributions were symmetric, and a Wilcoxon rank
um test otherwise. Variables are reported as mean  SD.
tatistical significance was set a priori at p  0.05.
esults
aseline characteristics. Table 1 lists the baseline charac-
eristics of the study population (median age 59 years; 55%
en). The majority of patients were completely asymptom-
tic (NYHA functional class I in 61.6%; CCS angina class
in 79.6%; both NYHA functional class I and CCS angina
lass I in 54.0%). Massive septal hypertrophy (30 mm in
.5%), an adverse family history of sudden death (present in
2.0%), and history of ICD (1.0%) were uncommon. The
verage peak LVOT gradient at rest was 40.9  35.8 mm
g, with 270 patients (49.6%) having a resting peak LVOT
radient of 30 mm Hg. In the remaining 274 patients
50.4%), the resting peak LVOT gradient was 30 mm Hg
t rest and 50 mm Hg following provocation.
urvival. Median follow-up for the entire cohort was 9.3
ears (range 6 days to 23 years). There were 178 deaths
32.7%) during follow-up (Table 2). Noncardiac etiologies
ere the cause of death in 81 patients (14.9%; 45.5% of all
eaths). HCM-related death occurred in 82 patients (46.1%
f all deaths). Sudden death occurred in 10 patients, none of
hom had previously been implanted with an ICD. Two
atients died after septal reduction therapy (1 myectomy, 1
nivariate and Multivariate Predictors of All-Cause MortalityTable 3 Univariate and Multivariate Predictors of All-Cause Mo
Univariate
Variable HR (95% CI)
Age (yrs) 1.07 (1.05–1.08)
Prior stroke 2.51 (1.54–4.10)
Resting LVOT gradient (mm Hg) 1.01 (1.00–1.01)
Male sex 0.44 (0.32–0.60)
Coronary artery disease 1.92 (1.16–3.17)
Atrial fibrillation 1.44 (0.95–2.19)
Hypertension 1.57 (1.17–2.12)
Diabetes 1.52 (0.82–2.80)
Left atrial volume index (cm/m2) 0.81 (0.59–1.11)
Septal thickness (mm) 1.02 (1.00–1.04)
End-diastolic dimension (mm) 1.01 (0.95–1.07)
End-systolic dimension (mm) 0.97 (0.94–1.01)I  confidence interval; HR  hazard ratio; other abbreviations as in Table 1.eptal ablation) that was performed for severe symptoms
hat developed during follow-up. Cause of death could not
e specified in 15 patients (2.8%).
Overall survival was 85.8% (95% CI: 82.6% to 89.0%) at
years and 69.3% (95% CI: 64.6% to 74.3%) at 10 years
Fig. 1). This observed survival was only slightly lower than
hat of the expected survival of a similar general U.S.
opulation of individuals, whose 5- and 10-year survival
stimates were 87.7% and 71.9%, respectively (p  0.04,
bserved vs. expected). Of note, 80 deaths (44.9% of all
eaths) occurred in patients after 80 years of age. Survival
ree of HCM-related death in the entire cohort was 94.5%
95% CI: 92.3% to 96.6%) at 5 years and 82.9% (95% CI:
8.7% to 87.4%) at 10 years.
There was a strong relation between the severity of the
VOT gradient at rest and the outcome. For patients with
igh resting LVOT gradients (velocity 4 m/s; n  111),
he 10-year survival free of all mortality was only 52.8%
95% CI: 41.4% to 67.2%) and was significantly lower than
he expected survival for this group of patients (69.2%; p 
.001 for expected vs. observed) (Fig. 2). Conversely,
atients with either peak LVOT velocity 3 m/s at rest
n  293) or peak resting velocity of 3 to 4 m/s (n  140)
ad normal survival. The 10-year survival for these 2 groups
f patients was 76.5% (95% CI: 70.6% to 82.9%; p  0.75
s. expected) and 65.9% (95% CI: 57.2% to 75.9%; p 0.37
s. expected), respectively (Fig. 2). Independent predictors
f all-cause mortality were age (hazard ratio [HR]: 1.07;
5% CI: 1.05 to 1.08; p  0.0001), prior stroke (HR: 1.75;
5% CI: 1.06 to 2.88; p  0.03), and resting LVOT
radient (HR: 1.005; 95% CI: 1.001 to 1.009; p  0.01)
Table 3). Severity of LVOT obstruction was also related to
ccurrence of HCM-related death (10-year survival, 70.7%
s. 82.4% vs. 86.8% for peak LVOT velocity at rest of 3
/s vs. 3 to 4 m/s vs. 4 m/s; p  0.02 for group
omparison) (Fig. 3).
eart failure and septal reduction therapy. One hundred
ourteen patients (21.0%) developed severe cardiac symp-
y
Multivariate
p Value HR (95% CI) p Value
0.0001 1.07 (1.05–1.08) 0.0001
0.0002 1.75 (1.06–2.88) 0.03
0.0001 1.005 (1.001–1.009) 0.01
0.0001 — —
0.01 — —
0.09 — —
0.0029 — —
0.19 — —
0.19 — —
0.06 — —
0.84 — —
0.14 — —rtalit
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Minimally Symptomatic Obstructive HCM July 14, 2009:234–41oms (NYHA functional class III/IV dyspnea or CCS class
II/IV angina) in follow-up, including 104 patients whose
evere symptoms occurred within 10 years after the initial
valuation. Fifty-one of these patients (9.2%) underwent
ither surgical myectomy (n 47) or alcohol septal ablation
n  4) at the onset of severe symptoms. Forty-eight of the
rocedures were undertaken within 10 years after the initial
valuation. The 10-year survival free of death and severe
ymptoms (including those requiring septal reduction ther-
py) in the overall population was 50.3% (95% CI: 45.3% to
5.8%). For the end point of HCM-related death and
evere symptoms, this survival was 59.4% (95% CI: 54.2% to
5.0%).
Survival free of severe symptoms was related to the
everity of LVOT obstruction. For patients with peak
VOT velocity at rest of 4 m/s, the 10-year survival free
f death and severe symptoms was only 31.7% (95% CI:
1.5% to 46.7%), and was significantly lower than patients
ith either peak LVOT velocity of3 m/s (58.1%; 95% CI:
1.5% to 65.6%) or peak LVOT velocity of 3 to 4 m/s
Figure 3
Survival Free of Definite or Probable HCM-
Related Death and Severe Cardiac Symptoms
According to Severity of the Peak LVOT Velocity
Increasing severity of the peak left ventricular outflow tract (LVOT) velocity was
directly related to occurrence of hypertrophic cardiomyopathy (HCM)-related
death and occurrence of severe cardiac symptoms (i.e., New York Heart Asso-
ciation functional class III or IV dyspnea or Canadian Cardiac Society class III
or IV angina). Occurrence of severe symptoms includes need for septal reduc-
tion therapy (i.e., surgical septal myectomy or percutaneous alcohol septal
ablation) during the follow-up period.46.7%; 95% CI: 38.0% to 57.5%; p  0.0001 for 3-group aomparison) (Fig. 3). Severity of the resting LVOT gradient
as an independent predictor of survival free of death and
evere symptoms in a multivariate model, which also iden-
ified age, male sex, and prior stroke as independent
ovariates of this end point (Table 4).
Development of severe symptoms in follow-up (entered as a
ime-dependent variable) also was significantly associated with
oorer survival in the multivariate model (HR: 1.71; 95% CI:
.11 to 2.65; p  0.02). Of note, the 10-year survival of the
30 patients who continued to remain free of severe symptoms
t follow-up was 66.5% (95% CI: 61.0% to 72.5%), which was
ot different than the expected survival of these 430 patients (p
0.18) (Fig. 4). However, the relation between the magnitude
f the resting LVOT gradient and death persisted even among
atients who avoided the development of severe symptoms in
ollow-up (p  0.0001) (Fig. 4). Excess mortality was present
mong patients with peak LVOT velocity4 m/s (p 0.007
s. observed), but not among the patients with less severe
bstruction (Fig. 5).
iscussion
he principal findings of this investigation are: 1) there is
nly a slight excess mortality in patients with obstructive
CM who self-report mild or no symptoms in comparison
o the expected survival for a similar general U.S. population
f individuals; 2) approximately one-half of the deaths can
e attributed to non–HCM-related causes in these patients;
) even in the absence of severe cardiac symptoms, the
agnitude of the resting LVOT gradient is directly and
ndependently associated with increasing risk of adverse
linical outcome; and 4) mildly symptomatic or asymptom-
tic patients with high LVOT gradients at rest (peak
elocity 4 m/s) have poorer than expected survival and are
t higher risk for severe heart failure.
Knowledge about the prognostic significance of LVOT
bstruction in patients with HCM is important as obstruction
ay be present in 65% of these patients, irrespective of
ardiac symptoms (20,21). Although the prognostic signifi-
ance of LVOT obstruction in HCM has been debated, recent
nalyses confirm that obstruction is associated with poorer
urvival (5–8). It has been shown that septal myectomy in
atients with obstruction and severe symptoms has a highly
avorable long-term outcome (11). These reports have
purred consideration about a possible role for relief of
VOT obstruction in the absence of significant cardiac
ymptoms, especially since surgical myectomy can now be
erformed with low risk (1%), particularly in younger
atients without comorbidities (11,22).
The present investigation examined the long-term sur-
ival of minimally symptomatic patients with obstructive
CM who were initially treated without surgical myec-
omy. Comparison to the expected survival of a similar age-
nd sex-matched cohort from the U.S. general population
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July 14, 2009:234–41 Minimally Symptomatic Obstructive HCMas performed to gain insight into whether or not these
atients have excess mortality (11,16,19). Overall, there was
nly a slight excess in observed mortality (10-year estimate,
9% vs. 72%). Although it can be difficult to determine the
ontribution of HCM to death in individuals with other
orbid conditions, approximately one-half of the deaths in
his population were attributable to noncardiac causes.
ased on these findings, prophylactic relief of LVOT
bstruction, either via surgical myectomy or percutaneous
ethods, is unlikely to significantly impact the longevity of
hese patients.
Patients with obstructive HCM and minimal symptoms,
owever, are at risk for developing heart failure. In this
tudy, severe cardiac symptoms developed in 114 (21.0%)
atients, and 48 of these underwent septal reduction therapy
ithin 10 years after their initial evaluation. These frequen-
ies are similar to prior reports on the natural history of
ther unselected HCM populations (1,23–26). Nonethe-
ess, an important finding of the present study was a direct,
ndependent relation between the severity of the LVOT
radient and both death and long-term occurrence of severe
ymptoms. In particular, for patients with high LVOT
radients (peak velocity 4 m/s), there was a significantly
ncreased incidence of heart failure and death that was not
resent at lower gradient thresholds. Among patients with
eak LVOT velocity at rest of 4 m/s, survival was 53%,
nd only 32% remained free of death and severe symptoms
t 10 years after the initial evaluation. Although these data
ay not be persuasive enough to make the case for surgery
r ablation in the absence of severe symptoms, they do
trongly support the need for frequent and close surveillance
f patients with HCM and severe LVOT gradients, even
hen symptoms are mild or not present at the initial
valuation. In this regard, particular attention to differenti-
ting the Doppler signal of LVOT obstruction from mitral
ymptomsy or Severe Symptoms
Multivariate
p Value HR (95% CI) p Value
0.0001 1.01 (1.004–1.023) 0.005
0.009 1.73 (1.08–2.77) 0.02
0.0001 1.006 (1.003–1.010) 0.0001
0.0001 0.56 (0.42–0.74) 0.0001
0.07 — —
0.07 — —
0.07 — —
0.0021 — —
0.96 — —
0.02 — —
0.65 — —
0.34 — —
0.37 — —
0.0076 — —Figure 4
Survival of Patients With Obstructive
HCM Who Remained Free of Severe
Cardiac Symptoms During the Follow-Up
(A) Expected versus observed survival. (B) Survival according to peak left ven-
tricular outflow tract (LVOT) velocity. There was no survival impairment for
patients who remained free of severe symptoms during follow-up. However, the
relation between the magnitude of the LVOT gradient to survival persisted in
patients who avoided the development of severe symptoms.nivariate and Multivariate Predictors of All-Cause Mortality or Severe STable 4 Univariate and Multivariate Predictors of All-Cause Mortalit
Univariate
Variable HR (95% CI)
Age 1.03 (1.02–1.03)
Prior stroke 1.87 (1.17–2.99)
Resting LVOT gradient 1.009 (1.005–1.012)
Male sex 0.45 (0.34–0.58)
Coronary artery disease 1.54 (0.97–2.44)
Diabetes 1.65 (0.96–2.83)
Atrial fibrillation 1.41 (0.98–2.02)
Hypertension 1.49 (1.16–1.93)
Beta-receptor antagonist use 0.99 (0.77–1.30)
End-diastolic dimension 0.97 (0.95–1.00)
End-systolic dimension 0.99 (0.97–1.02)
Septal thickness 1.01 (0.99–1.04)
Posterior wall thickness 1.02 (0.97–1.08)
Left atrial volume index 1.02 (1.01–1.04)egurgitation is needed.
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Minimally Symptomatic Obstructive HCM July 14, 2009:234–41The present investigation was a nonrandomized, retro-
pective analysis with known limitations of such studies. A
andomized trial of septal reduction versus medical therapy
ould be the optimal method for examining the most
ppropriate treatment of these patients. Of note, in this
tudy, there was a survival difference of 2.0% at 5 years of
ollow-up. In order to have 80% power to detect this
ifference in a 5-year prospective study, 4,436 patients
ould need to be randomized into each therapeutic arm.
uch a study would require screening of 30,000 HCM
atients if the trial was able to enroll 20% of patients
creened (27). This high number of patients significantly
educes the feasibility of a prospective treatment trial that
ould address the study aims of the present investigation. A
reatment trial that restricted enrollment to patients with
igh LVOT gradients might require enrollment of fewer
tudy patients. In the absence of such data, consensus about
he management of these patients will continue to rely on
bservational studies such as the present investigation (27).
For asymptomatic patients with valvular heart disease,
arly surgery increasingly is being advocated in an effort to
void detrimental, irreversible ventricular remodeling due to
ncreased ventricular load (28). With the advent of modern
urgical techniques, the risk of surgery has become lower
nd more favorable to this approach in appropriately se-
ected patients. For example, in low-risk asymptomatic
atients with severe aortic stenosis (operative mortality
1%), early surgery may be considered because of the high
requency of subsequent adverse clinical events that have
een observed in recent analyses of these patients (16,19).
Conversely, for patients with HCM, estimating the
linical burden of the systolic contraction load due to
VOT obstruction poses unique challenges. Heterogeneity
haracterizes the phenotypic expression and natural history
f HCM. The LVOT gradient is labile due to its sensitivity
o ventricular loading conditions (20,21,29). Although relief
f LVOT obstruction can result in regression of myocardial
ypertrophy, severity of hypertrophy is a primary phenom-
non that occurs independently of LVOT obstruction and
hus does not accurately reflect adverse ventricular load in
CM. The present study relied on patient self-reporting of
ymptoms. Exercise testing may reveal previously unrecog-
ized functional limitation, leading to septal reduction
herapy in some instances. The present study did not
xamine patients who had mild symptoms (NYHA func-
ional class II or lower) and underwent septal reduction
herapy for lifestyle impairment (9).
Nonetheless, onset of severe symptoms independently
redicted poorer survival and was frequent in patients with
igh LVOT gradients. Although these data do not support
urgical relief of LVOT obstruction for minimally symp-
omatic patients, such patients should be followed with
wareness of the potential for symptoms to progress and the
evelopment of heart failure. Few (2%) patients hadFigure 5
Observed Versus Expected Survival of Patients
With Obstructive Hypertrophic Cardiomyopathy Who
Remained Free of Severe Symptoms in Follow-Up
Expected survival was calculated from age- and sex-matched U.S. general pop-
ulation mortality rates and year of entry. (A) Expected versus observed survival
for patients with peak left ventricular outflow tract (LVOT) velocity 3 m/s.
(B) Expected versus observed survival for patients with peak LVOT velocity 3 to
4 m/s. (C) Expected versus observed survival for patients with peak LVOT
velocity 4 m/s.ocumented sudden cardiac death in this study, although
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July 14, 2009:234–41 Minimally Symptomatic Obstructive HCMncertainty about the specific cause of death was present in
number of patients.
Although all patients in this study had evidence of
ynamic LVOT obstruction, the present analyses focused
n the relation between long-term outcome and severity of
he LVOT gradient under basal conditions (i.e., at rest).
he present study demonstrates a relation between magni-
ude of the resting LVOT gradient and prognosis, which
as not been evident in previous analyses. The present
bservation may be due to differences in unique clinical
haracteristics of the study population such as a relatively
lder age (median 59 years) as well as inclusion of patients
ith lower LVOT gradients (mean 41 mm Hg). Severity of
VOT gradients observed with provocation were not ex-
mined due to the different methods (e.g., Valsalva strain,
myl nitrite inhalation) used to determine latent obstruc-
ion. Currently, comparison data for these methods and
heir prognostic implications are limited (30,31). Further
nalyses of the clinical significance of the different methods
or evaluating latent obstruction and the potential impact of
gents used to lessen its severity (i.e., beta-receptor antag-
nists, calcium-channel antagonists, disopyramide) are war-
anted (32). These data would be of particular relevance for
inimally symptomatic patients with obstructive HCM, for
hom septal reduction therapy currently is not advised.
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